Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 8/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.55 |
| ▸ | SYK | P43405 | 8/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.41 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29717699 | 1.00 | MAPK8 (0.55) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666605 | 1.00 | MAPK8 (0.55) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL29717686 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL29717652 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666532 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666534 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666661 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666660 | 0.96 | MAPK8 (0.51) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666279 | 0.94 | MAPK8 (0.49) | MAPK8MAPK9SYKPDGFRBPDGFRA | |
| SCHEMBL19666631 | 0.94 | MAPK8 (0.49) | MAPK8MAPK9SYKPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | CELGENE CORPORATION (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | CELGENE CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010555-B2 | Animal and human anti-trypanosomonal and anti-leishmania agents | TPMT, TYMP, ATIC | MAPK8 1870/4885MAPK9 2986/4885SYK 4069/4885 |
| US-20170348315-A1 | ANIMAL AND HUMAN ANTI-TRYPANOSOMONAL AND ANTI-LEISHMANIA AGENTS | TPMT, TYMP, ATIC | MAPK8 1870/4885MAPK9 2986/4885SYK 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.